Article
[A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 20 Jun 2025
Wei L, Shang J, An X, Zhang G Q, Guan Y J, Piao H X, Jin J L, Bai L, Yang X X, Yang D K, Luo X H, Yuan S F, Zhao Y R, Ma Y J, Li G M, Lin F, Wu X P, Geng J W, Zou G Z, Chang J B, Gong Z J, Mao X R, Zhu J, Guo W T, He Q W, Luo L, Zhuang Y L, Xie H M, Zhang Y J
Abstract excerpt
Objective: To assess the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of chronic hepatitis C (CHC) of various genotypes, without cirrhosis or with compensated cirrhosis. Methods: 394 cases with CHC from 22 centers were collected from October 2021 to April 2023. They were randomly assigned to receive either the experimental drugs (antaitasvir phosphate 100...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
